

DESCUBRA TODO EL POTENCIAL

OZEMPIC® semaglutida

El nuevo AR GLP-1 **semanal** con **eficacia clínica superior¹⁻⁶** y **beneficio cardiovascular⁸** en pacientes adultos con diabetes tipo 2 que otorga:^{9,10}



**CONTROL
GLICÉMICO
SUPERIOR¹⁻⁶**



**PÉRDIDA DE
PESO SUPERIOR Y
SOSTENIDA^{1-6*}**



**BENEFICIO
CARDIOVASCULAR
DEMOSTRADO[†]**

AR GLP-1: agonista del receptor del péptido similar al glucagón tipo 1; CV - cardiovascular.
*Resultados aplican a Ozempic® por estudios SUSTAIN que incluyeron placebo, Sitagliptina, Exenatida ER, Glargina U100, Canagliflozina y Liraglutida. †En SUSTAIN 6, Ozempic® redujo riesgo CV (muerte CV, infarto de miocardio (IM) no fatal y accidente cerebrovascular no fatal) versus placebo en pacientes adultos con diabetes tipo 2 con alto riesgo CV tratado con estándar de cuidado de diabetes y riesgo CV

Para mayor información acceda a nuestra página web
www.novonordisk.cl

El Folleto de información al profesional autorizado
por ISP disponible escaneando el siguiente código QR



Novo Nordisk® Farmaceutica Limitada
Avda. Presidente Riesco 5335 Oficina 504. Las Condes, Santiago, Chile.
Tel: +56-2-2428 3200 | Website: www.novonordisk.cl | CL200ZM00032

OZEMPIC®
semaglutida

Referencias: 1. Sorri C et al. Efficacy and safety once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial Lancet Diabetes Endocrinol 2017;5:251-260. 2. Ahren B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56 week, double-blind, 3a phase, randomised trial Lancet Diabetes Endocrinol 2017;5:341-354. 3. Ahman AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): a 56 week, open-label, randomized Clinical Trial. Diabetes Care 2017;DOI: 10.2337/dci17-0417. 4. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3[†] trial. Lancet Diabetes Endocrinol. 2017;5(5):355-366. 5. Rodbard HW, Lingway I, Reed J, et al. Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5). Presented at Annual Meeting of the European Association for the Study of Diabetes (EASD), 12-16 September 2016, Munich, Germany. Poster number 766. 6. Pratley RE, Aroda VR, Lingway I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018. Doi.org/10.1016/S2213-8587(18)30024-X. 7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). N Engl J Med 2016;375:1834-1844. 8. Zinman B, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019. Doi:10.1016/S2213-8587(19)30311-0. 9. Lingway I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019. Doi:10.1016/S2213-8587(19)30311-0. 10. Caperhorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2019. doi:10.1016/j.diabet.2019.101117 2019 May;7(5):356-367.